These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34690072)

  • 1. Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.
    Franchini M; Mengoli C; Ballotari A; Glingani C
    Transfus Clin Biol; 2022 May; 29(2):186-187. PubMed ID: 34690072
    [No Abstract]   [Full Text] [Related]  

  • 2. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
    Hirani R; Hoad V; Gosbell IB; Irving DO
    Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABO blood group does not influence the level of anti-SARS-CoV-2 antibodies in convalescent plasma donors.
    Žiberna K; Jež M; Jazbec K; Mali P; Potokar UR; Rožman P
    Transfusion; 2022 Mar; 62(3):556-562. PubMed ID: 35041206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
    Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
    Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.
    Bloch EM; Patel EU; Marshall C; Littlefield K; Goel R; Grossman BJ; Winters JL; Shrestha R; Burgess I; Laeyendecker O; Shoham S; Sullivan D; Gehrie EA; Redd AD; Quinn TC; Casadevall A; Pekosz A; Tobian AAR
    Vox Sang; 2021 Aug; 116(7):766-773. PubMed ID: 33493365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
    Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
    Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
    Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL
    Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.
    Nurmi V; Knight C; Estcourt L; Hepojoki J; Lamikanra AA; Tsang HP; Roberts DJ; Polack FP; Simmonds P; Hedman K; Alvarez-Paggi D; Harvala H
    J Infect Dis; 2023 Aug; 228(3):245-250. PubMed ID: 36967714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
    Barnes TW; Schulte-Pelkum J; Steller L; Filchtinski D; Jenness R; Williams MR; Kober C; Manni S; Hauser T; Hahn A; Kalina U; Simon TL; Schuetz P; Roth NJ
    Clin Immunol; 2021 Nov; 232():108871. PubMed ID: 34619377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.
    Gharbharan A; GeurtsvanKessel CH; Jordans CCE; Blaauw M; van der Klift M; Hassing RJ; Smits-Zwinkels M; Meertens M; van den Hout EC; de Man AM; Hageman I; Bogers S; van der Schoot CE; Swaneveld F; Anas AA; Rokx C; Rijnders BJA
    Clin Infect Dis; 2022 Apr; 74(7):1271-1274. PubMed ID: 34293119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.
    Jahrsdörfer B; Groß R; Seidel A; Wettstein L; Ludwig C; Schwarz T; Körper S; Rojewski M; Lotfi R; Weinstock C; Seifried E; Corman VM; Drosten C; Münch J; Schrezenmeier H
    J Immunol; 2021 Jun; 206(11):2614-2622. PubMed ID: 33980583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.
    Martin MC; Jimenez A; Ortega N; Parrado A; Page I; Gonzalez MI; Blanco-Peris L
    PLoS One; 2022; 17(2):e0264124. PubMed ID: 35202394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS COV-2- IgG antibodies in blood donors in pandemic - A game changer for policy makers.
    Mahapatra S
    Transfus Clin Biol; 2022 Feb; 29(1):11-15. PubMed ID: 34653615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.
    Franchini M; Glingani C; Liumbruno GM; Mengoli C
    Transfus Apher Sci; 2021 Dec; 60(6):103216. PubMed ID: 34315677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.